NCBiotech Transforms Life Sciences in North Carolina

(Editor Note: This story originally appeared in the NC State News.)

For almost as long as NC State University has existed, sports rivals have teasingly called us Moo U or Cow College, thanks to our strengths in agricultural research and education.

So it’s only right that decades of groundwork at NC State might one day help cattle farmers worldwide better control their livestock’s gut microbiome — a collection of microbes that aid digestion — and cool the climate as a result.

Results from a collaborative project between Tiamat Sciences and BIOMILQ — women-owned biotechnology startups in Research Triangle Park — show the promise of using plant-based proteins to lower the cost of producing food using cultured cells.  

Astellas Pharma Inc. announced that it will acquire Propella Therapeutics, Inc., based in Pittsboro. Propella is a privately held biopharmaceutical company that has leveraged a wholly owned proprietary platform that combines medicinal chemistry with lymphatic targeting to create new oncology drugs.

Through the acquisition of Propella, Astellas will acquire PRL-02 (abiraterone decanoate), an androgen biosynthesis inhibitor being developed by Propella to treat prostate cancer. 

(Editor Note: This story originally appeared in the NC State News.)

For almost as long as NC State University has existed, sports rivals have teasingly called us Moo U or Cow College, thanks to our strengths in agricultural research and education.

So it’s only right that decades of groundwork at NC State might one day help cattle farmers worldwide better control their livestock’s gut microbiome — a collection of microbes that aid digestion — and cool the climate as a result.

Results from a collaborative project between Tiamat Sciences and BIOMILQ — women-owned biotechnology startups in Research Triangle Park — show the promise of using plant-based proteins to lower the cost of producing food using cultured cells.  

Astellas Pharma Inc. announced that it will acquire Propella Therapeutics, Inc., based in Pittsboro. Propella is a privately held biopharmaceutical company that has leveraged a wholly owned proprietary platform that combines medicinal chemistry with lymphatic targeting to create new oncology drugs.

Through the acquisition of Propella, Astellas will acquire PRL-02 (abiraterone decanoate), an androgen biosynthesis inhibitor being developed by Propella to treat prostate cancer. 

(Editor Note: This story originally appeared in the NC State News.)

For almost as long as NC State University has existed, sports rivals have teasingly called us Moo U or Cow College, thanks to our strengths in agricultural research and education.

So it’s only right that decades of groundwork at NC State might one day help cattle farmers worldwide better control their livestock’s gut microbiome — a collection of microbes that aid digestion — and cool the climate as a result.

Results from a collaborative project between Tiamat Sciences and BIOMILQ — women-owned biotechnology startups in Research Triangle Park — show the promise of using plant-based proteins to lower the cost of producing food using cultured cells.  

Astellas Pharma Inc. announced that it will acquire Propella Therapeutics, Inc., based in Pittsboro. Propella is a privately held biopharmaceutical company that has leveraged a wholly owned proprietary platform that combines medicinal chemistry with lymphatic targeting to create new oncology drugs.

Through the acquisition of Propella, Astellas will acquire PRL-02 (abiraterone decanoate), an androgen biosynthesis inhibitor being developed by Propella to treat prostate cancer. 

(Editor Note: This story originally appeared in the NC State News.)

For almost as long as NC State University has existed, sports rivals have teasingly called us Moo U or Cow College, thanks to our strengths in agricultural research and education.

So it’s only right that decades of groundwork at NC State might one day help cattle farmers worldwide better control their livestock’s gut microbiome — a collection of microbes that aid digestion — and cool the climate as a result.

Results from a collaborative project between Tiamat Sciences and BIOMILQ — women-owned biotechnology startups in Research Triangle Park — show the promise of using plant-based proteins to lower the cost of producing food using cultured cells.  

Astellas Pharma Inc. announced that it will acquire Propella Therapeutics, Inc., based in Pittsboro. Propella is a privately held biopharmaceutical company that has leveraged a wholly owned proprietary platform that combines medicinal chemistry with lymphatic targeting to create new oncology drugs.

Through the acquisition of Propella, Astellas will acquire PRL-02 (abiraterone decanoate), an androgen biosynthesis inhibitor being developed by Propella to treat prostate cancer.